Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 29, 2018Clinical Pharmacology & TherapeuticsOpen Access

Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAjit SuriTakeda (United States)DMDiane R. MouldPhoenixville HospitalYLYi LiuUniversity of Science and Technology of China

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Suri et al. (2018) studied this question.

synapsesocial.com/papers/6a7f3524b4cedf233c7ca053https://doi.org/10.1002/cpt.1037
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment2016 · 63 citations
  2. 2Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies2017 · 63 citations
  3. 3Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia2016 · 25 citations
  4. 4Toward Greater Insights on Pharmacokinetics and Exposure–Response Relationships for Therapeutic Biologics in Oncology Drug Development2017 · 51 citations
  5. 5Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors2016 · 265 citations